Fate Therapeutics Inc
FATE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001434316
In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 1 sale; 157 institutions reported holding it in 13F filings for Q2 2026, worth $193.2M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:48 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $136.3M (2051.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Mar 5, 2025 | Feb 26, 2024 | Feb 28, 2023 | Feb 28, 2022 |
| Revenue | $6.65M | $13.6M | $63.5M | $96.3M | $55.8M |
| Operating expenses | $154.3M | $223.9M | $254.0M | $404.7M | $272.8M |
| Research and development | $107.8M | $135.0M | $172.6M | $320.5M | $215.5M |
| Selling, general and administrative | $46.5M | $74.2M | $81.4M | $84.2M | $57.3M |
| Operating income | -$147.7M | -$210.3M | -$190.5M | -$308.4M | -$217.0M |
| Interest expense | – | – | – | – | $0 |
| Income tax | $2.00K | $0 | $0 | $0 | $0 |
| Net income | -$136.3M | -$186.3M | -$160.9M | -$281.7M | -$212.2M |
| EPS, basic | $-1.15 | $-1.64 | $-1.64 | $-2.91 | – |
| EPS, diluted | $-1.15 | $-1.64 | $-1.64 | $-2.91 | – |
| Weighted shares, basic | 118.8M | 113.7M | 98.4M | 96.8M | – |
| Weighted shares, diluted | 118.8M | 113.7M | 98.4M | 96.8M | – |
| Margins and growth | |||||
| Operating margin | -2222.4% | -1542.6% | -299.9% | -320.2% | -388.6% |
| Net margin | -2051.1% | -1366.5% | -253.3% | -292.5% | -379.9% |
| Revenue growth, year over year | −51.2% | −78.5% | −34.0% | +72.4% | +77.7% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Mar 5, 2025 | Feb 26, 2024 | Feb 28, 2023 | Feb 28, 2022 |
| Cash and equivalents | $46.6M | $36.1M | $41.9M | $61.3M | $133.6M |
| Short-term investments | $157.0M | $243.0M | $273.3M | $374.9M | – |
| Accounts receivable | $916.0K | $3.54M | $1.83M | $38.5M | $8.68M |
| Total current assets | $208.7M | $291.9M | $331.5M | $502.1M | $633.4M |
| Property, plant and equipment | $56.9M | $64.4M | $96.8M | $110.0M | $91.5M |
| Total assets | $318.9M | $440.7M | $506.2M | $705.6M | $921.5M |
| Accounts payable | $2.66M | $9.37M | $4.72M | $8.27M | $8.61M |
| Total current liabilities | $36.1M | $38.5M | $39.1M | $114.1M | $81.3M |
| Shareholders' equity | $207.2M | $318.7M | $368.4M | $483.9M | $678.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Mar 5, 2025 | Feb 26, 2024 | Feb 28, 2023 | Feb 28, 2022 |
| Operating cash flow | -$106.1M | -$122.9M | -$132.3M | -$248.2M | -$162.9M |
| Capital expenditures | $5.95M | $730.0K | $6.15M | $35.6M | $50.7M |
| Free cash flow | -$112.0M | -$123.6M | -$138.4M | -$283.8M | -$213.6M |
| Depreciation and amortization | $12.9M | $19.0M | $18.3M | $13.8M | $5.85M |
| Stock-based compensation | $24.9M | $41.5M | $43.5M | $78.7M | $54.4M |
| Investing cash flow | $111.2M | $12.2M | $112.7M | $166.8M | -$324.0M |
| Financing cash flow | $5.49M | $99.9M | $85.0K | $9.21M | $453.1M |
| Net change in cash | $10.6M | -$10.8M | -$19.5M | -$72.3M | -$33.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 375.0% | 304.4% | 68.4% | 81.8% | 97.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 121.6M | +5.4% | SEC |
| Aug 6, 2026 | 119.8M | +3.9% | SEC |
| May 7, 2026 | 116.6M | +1.7% | SEC |
| Feb 19, 2026 | 116.3M | +1.5% | SEC |
| Nov 6, 2025 | 115.4M | +1.3% | SEC |
| Aug 5, 2025 | 115.3M | +1.3% | SEC |
| May 6, 2025 | 114.6M | +0.7% | SEC |
| Feb 25, 2025 | 114.6M | +15.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.